inv(16)(p13q22) CBFB/MYH11 in treatment related leukemia
2003-10-01 Jean-Loup Huret   Affiliation1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
Treatment related myelodysplasia (t-MDS) or acute myeloid leukaemias (t-AML)
Note
The study included 48 cases; t-MDS without progression to AML accounted for 8%, t-MDS with progression to AML for 13% and t-AML for the remaining 79% the AML subtype was M4eo in 83%, M2 in 14%; no case of acute lymphoblastic leukaemia
Epidemiology
inv(16)(p13q22) was found in 9% of t-MDS/t-AML; sex ratio: 18M/30F
Clinics
Age at diagnosis of the primary disease 43 yrs (range 6-75); age at diagnosis of the t-MDS/t-AML: 48 yrs (range 13-77). Median interval was short: 22 mths (range: 8-533). Primary disease was a solid tumor in 71% of cases (in particular breast cancer, sarcoma, cancer of the ovary) and a hematologic malignancy in 27%, treatment was radiotherapy (21%, a relatively high proportion compared to other groups), chemotherapy (29%), or both (50%). Treatment included topoisomerase II inhibitors in 60% of cases and alkylating agents in 63%.
Prognosis
Patients under 55 yrs of age had better outcome. Median survival was 29 mths, with 45% of patients surviving at 5 yrs, the best survival among subgroups of treatment related leukemias with a balanced chromosome aberration (patients with 11q23 rearrangement, 3q21q26 rearrangement, 12p13 rearrangement, t(9;22), t(8;16), or a 21q22 rearangement)). Patients with t(15;17) had similar median survival, but less long term survivors.
Genes Involved and Proteins
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 31817911 | 2019 | Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription. | 150 |
| 34440157 | 2021 | How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. | 123 |
| 38061017 | 2023 | Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein. | 112 |
| 32831296 | 2020 | CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. | 93 |
| 36874378 | 2023 | Therapy-related core binding factor acute myeloid leukemia. | 86 |
| 29755956 | 2018 | Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia. | 81 |
| 34804441 | 2021 | Gastrointestinal Myeloid Sarcoma a Case Presentation and Review of the Literature. | 80 |
| 27798625 | 2016 | The genomic landscape of core-binding factor acute myeloid leukemias. | 79 |
| 40763310 | 2025 | CBFβ-SMMHC-driven leukemogenesis requires enhanced RUNX1-DNA binding affinity in mice. | 72 |
| 37019972 | 2023 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | 71 |
| 34686664 | 2021 | Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. | 70 |
| 34336831 | 2021 | CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML. | 67 |
| 42933890 | 2026 | CBFB-MYH11 directly activates TGFβ and PD-L1 to drive immune evasion in acute myeloid leukemia. | 66 |
| 33730843 | 2022 | Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. | 54 |
| 40829168 | 2025 | Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging. | 52 |
| 35973983 | 2022 | Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. | 52 |
| 33836581 | 2021 | Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells. | 51 |
| 38936913 | 2024 | Molecular and Clinical Insights in the Increasing Detection of BCR::ABL1 p190+ in Adult Acute Myeloid Leukemia Patients. | 50 |
| 40156426 | 2025 | The Fusion Genes and Their Relation with Genetic Variants in Egyptian AML Patients. | 48 |
| 36442087 | 2022 | Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia. | 47 |
| 32929473 | 2020 | RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development. | 47 |
| 31624376 | 2020 | Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice. | 46 |
| 39966122 | 2025 | Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemia. | 45 |
| 30742053 | 2019 | IL1RL1 is dynamically expressed on Cbfb-MYH11(+) leukemia stem cells and promotes cell survival. | 43 |
| 35251131 | 2022 | Fusion Gene Detection Using Whole-Exome Sequencing Data in Cancer Patients. | 43 |
| 41294667 | 2025 | Unveiling the Genetic Mosaic of Pediatric AML: Insights from Southwest China. | 43 |
| 37699001 | 2023 | Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing. | 42 |
| 34771519 | 2021 | CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. | 42 |
| 29018080 | 2017 | Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11. | 41 |
| 31896782 | 2020 | The clinical mutatome of core binding factor leukemia. | 40 |
| 41300735 | 2025 | CBFB::MYH11 Fusion Located on a Supernumerary Ring Chromosome 16 in Pediatric Acute Myeloid Leukemia: Diagnostic Challenges and Prognostic Implications. | 39 |
| 35794567 | 2022 | Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD-positive acute myeloid leukemia. | 37 |
| 34547772 | 2021 | CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. | 35 |
| 41173205 | 2026 | Cohesin haploinsufficiency is tolerated in Cbfb::MYH11-driven murine acute myeloid leukemia. | 35 |
| 38493200 | 2024 | Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies. | 34 |
| 36939402 | 2023 | Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study. | 33 |
| 40304077 | 2025 | Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia. | 33 |
| 35497938 | 2022 | Therapy-related acute myeloid leukemia: A case series. | 30 |
| 39020534 | 2024 | Classic and molecular cytogenetic findings in leukemia patients from the Western part of Romania. | 23 |
| 34660293 | 2021 | Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia. | 20 |
| 20421454 | 2010 | Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins. | 19 |
| 42533004 | 2026 | Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine. | 15 |
| 37225965 | 2023 | Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing. | 14 |
| 33816105 | 2021 | Primary peritoneal myeloid sarcoma in association with CBFB/MYH11 fusion. | 13 |
| 41152985 | 2025 | Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution. | 13 |
| 37591621 | 2023 | Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications. | 11 |
| 22228403 | 2012 | Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. | 10 |
| 34512985 | 2021 | Abnormal eosinophils with immature eosinophilic granules in chronic myeloid leukemia in accelerated phase. | 2 |
| 38153768 | 2023 | CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia. | 0 |
| 22032582 | 2011 | Core-binding factor acute myeloid leukemia. | 0 |
| 35622005 | 2022 | AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome. | 0 |
| 32202250 | 2021 | Detection of del(16q) using the CBFB-MYH11 translocation dual fusion probe. | 0 |
| 36653696 | 2023 | Comprehensive molecular understanding of pediatric acute myeloid leukemia. | 0 |
| 19215983 | 2009 | Aleukemic bcr-abl positive granulocytic sarcoma. | 0 |
| 33162510 | 2020 | [Clinical significance of MRD in AML]. | 0 |
| 36039018 | 2022 | Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia. | 0 |
| 40931047 | 2025 | Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML. | 0 |
| 34546543 | 2022 | All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16. | 0 |
| 28299661 | 2017 | Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia. | 0 |
| 38388794 | 2024 | Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11. | 0 |
| 42135516 | 2026 | CBFB::MYH11 MRD after the second chemotherapy cycle: a guide for allogeneic transplantation in favorable-risk AML. | 0 |
| 37102302 | 2023 | TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia. | 0 |
| 31671434 | 2020 | Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen. | 0 |
| 32652328 | 2020 | IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia. | 0 |
| 39905935 | 2025 | Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison. | 0 |
| 35128634 | 2022 | TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event. | 0 |
| 24002588 | 2014 | CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia. | 0 |
| 34183780 | 2021 | Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11. | 0 |
| 31612466 | 2020 | Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. | 0 |
| 41966916 | 2026 | SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable? | 0 |
| 30006258 | 2018 | Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. | 0 |
| 26891877 | 2016 | Leukemogenic potency of the novel FLT3-N676K mutant. | 0 |
| 8751466 | 1996 | The gene product of CBFB-MYH11. | 0 |
| 25635758 | 2015 | Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. | 0 |
| 34674982 | 2022 | Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype. | 0 |
| 40293351 | 2025 | Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia. | 0 |
| 31353165 | 2020 | Detection of a novel CBFB-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22). | 0 |
| 38447191 | 2024 | A Case of a Patient with Therapy-related Core Binding Factor (CBF) Acute Myeloid Leukemia (CBF-AML). | 0 |
| 39803562 | 2024 | Loss of the Inv(16) Oncogene CBFB::MYH11 Eliminates Leukemia from the Blood and Spleen, but not the Bone Marrow. | 0 |
| 30919505 | 2019 | Measurable residual disease testing for personalized treatment of acute myeloid leukemia. | 0 |
| 28299658 | 2017 | Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders. | 0 |
| 30695313 | 2016 | [Case Conference of Hematological Malignancies Based on the Morphology of Blood Cells: Chairmen's Introductory Remarks]. | 0 |
| 21198299 | 2010 | Incidence and prognostic importance of molecular genetic defects in children with acute myeloblastic leukemia. | 0 |
| 28906004 | 2017 | Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic insertion of cbfb resulting in cbfb-Myh11 fusion. | 0 |
| 32492002 | 2020 | [Driver Mutations in Acute Myeloid Leukemia with Inversion of Chromosome 16]. | 0 |
| 28735486 | 2017 | Detection and Quantification of Acute Myeloid Leukemia-Associated Fusion Transcripts. | 0 |
| 35531760 | 2022 | Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. | 0 |
| 12239155 | 2002 | Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. | 0 |
| 27468869 | 2016 | Incidence of preleukemic fusion genes in healthy subjects. | 0 |
| 39182671 | 2024 | Tailored Digital PCR Follow-Up of Rare Fusion Transcripts after Initial Detection through RNA Sequencing in Hematological Malignancies. | 0 |
| 11561156 | 2001 | Function of the inv(16) fusion gene CBFB-MYH11. | 0 |
| 41139231 | 2025 | Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single-center validation study. | 0 |
| 12172539 | 2002 | Altered affinity of CBF beta-SMMHC for Runx1 explains its role in leukemogenesis. | 0 |
| 34674615 | 2021 | Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia. | 0 |
| 39659145 | 2025 | Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial. | 0 |
| 30277115 | 2019 | Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients. | 0 |
| 41250875 | 2026 | Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited. | 0 |
| 8630430 | 1996 | Novel CBFB-MYH11 fusion transcripts or reverse transcription-polymerase chain reaction artifacts? | 0 |
| 7577615 | 1995 | Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. | 0 |
| 38084551 | 2023 | Therapy-related acute myeloid leukemia with CBFB/MYH11 in a patient with ovarian cancer after exposure to chemotherapy. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 11921273 | 2002 | Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. | Andersen MK et al |
Summary
Fusion gene
CBFB/MYH11 CBFB (16q22.1) MYH11 (16p13.11) M ins(16)(q22p13p13) ins(16;16)(q22;p13p13) inv(16)(p13q22) t(16;16)(p13;q22)|CBFB/MYH11 CBFB (16q22.1) MYH11 (16p13.11) TIC
Note
This data is extracted from a very large study from an International Workshop on treatment related leukemias - restricted to balanced chromosome aberrations (i.e.: -5/del(5q)and -7/del(7q) not taken into account per see), published in Genes,Chromosomes and Cancer in 2002.

inv(16)(p13q22) CBFB/MYH11 and t(16;16)(p13;q22) CBFB/MYH11 Top: inv(16) FISH and diagram - Courtesy Hossein Mossafa; Middle Left: first row: inv(16)(p13q22) G-banding - Courtesy Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap, UW Cytogenetic Services; second row - Courtesy Hossein Mossafa; Middle Right: t(16;16)(p13;q22) u2013 Courtesy Adriana Zamecnikova; Bottom: Fluorescence in situ hybridization with the Vysis LSI CBFB break apart probe (Abbott Molecular, US) showing disruption of the gene as a result of (A) inv(16) and (B) its translocation to der(16) as a result of t(16;16) u2013 Courtesy Adriana Zamecnikova - Courtesy Adriana Zamecnikova.
Citation
Jean-Loup Huret
inv(16)(p13q22) CBFB/MYH11 in treatment related leukemia
Atlas Genet Cytogenet Oncol Haematol. 2003-10-01
Online version: http://atlasgeneticsoncology.org/haematological/1297/inv(16)(p13q22)
